Peng Zhang

Peng Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
ZLZhang Liu
Zhang Liu
ZSZile Shen
Zile Shen
WZWangfu Zang
Wangfu Zang
JZJian Zhou
Jian Zhou
ZYZhen Yu
Zhen Yu
XYXialin Yan
Xialin Yan
The Global Leadership Initiative on Malnutrition (GLIM) has achieved a consensus for the diagnosis of malnutrition in recent years. This study aims to determine the prognostic effect of the GLIM after cardiac surgery. A total of 603 patients in the training cohort and 258 patients in the validation cohort were enrolled in this study. Perioperative characteristics and follow-up data were collected. A nomogram based on independent prognostic predictors was developed for survival prediction. In total, 114 (18.9%) and 48 (18.6%) patients were defined as being malnourished according to the GLIM criteria in the two cohorts, respectively. Multivariate regression analysis showed that GLIM-defined malnutrition was an independent risk factor of total complication (OR 1.661, 95% CI: 1.063–2.594) and overall survival (HR 2.339, 95% CI: 1.504–3.637). The c-index was 0.72 (95% CI: 0.66–0.79) and AUC were 0.800, 0.798, and 0.780 for 1-, 2-, and 3-year survival prediction, respectively. The calibration curves of the nomogram fit well. In conclusion, GLIM criteria can efficiently identify malnutrition and has a prognostic effect on clinical outcomes after cardiac surgery. GLIM-based nomogram has favorable performance in survival prediction.

20 June 2023 in Experimental Gerontology
Verified
Journal Article
Open access
ZSZi-Le Shen
Zi-Le Shen
WCWen-Hao Chen
Wen-Hao Chen
ZLZhang Liu
Zhang Liu
DYDing-Ye Yu
Ding-Ye Yu
WCWei-Zhe Chen
Wei-Zhe Chen
ZYZhen Yu
Zhen Yu
Sarcopenia is an age-related skeletal muscle disorder that causes falls, disability and death in the elderly, but its exact mechanism remains unknown. In this study, we merged three GEO datasets into the expression profiles of 118 samples and screened 22 differentially expressed genes (DEGs) as candidate genes. Pathway analysis demonstrated that the functional enrichment of DEGs is mainly in the cellular response to insulin stimulus, PPAR signaling pathway and other metabolism-related pathways. Then, we identified six key genes by machine learning, which were confirmed to be closely associated with sarcopenia by bioinformatics analysis. It was experimentally verified that SCD1 exhibits the most substantial alterations in the progression of sarcopenia with disturbed lipid metabolism and myosteatosis. In addition, the immune microenvironment of sarcopenia was found to be affected by these key genes, with Th17 cells down-regulated and NK cells up-regulated. Sarcopenic patients consequently presented a more significant systemic inflammatory state with higher CAR (p = 0.028) and PAR (p = 0.018). For the first time, we identified key genes in sarcopenia with high-throughput data and demonstrated that key genes can regulate the progression of sarcopenia by affecting the immune microenvironment. Among them, SCD1 may influence lipid metabolism and myosteatosis process. Screening of key genes and analyzing of immune microenvironment provide a more accurate target for treating sarcopenia.


1 January 2026 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
ZSZile Shen
Zile Shen
ZLZhang Liu
Zhang Liu
GHGuowei Huang
Guowei Huang
LCLian Cui
Lian Cui
WCWenhao Chen
Wenhao Chen
ZYZhen Yu
Zhen Yu
Background: Sarcopenia is a progressive and systemic skeletal muscle disorder characterized by the decline of muscle mass and function. Despite its early‐stage, ‘possible sarcopenia’ has been emphasized for prompt intervention; there are currently no specific biomarkers for the diagnosis and treatment. Methods: RNA sequencing of human skeletal muscle across sarcopenia stages identified CCN5. Adeno‐associated virus (AAV) is intramuscularly injected into young C57BL/6J mice to knockdown CCN5 in skeletal muscle. Phenotypic alterations are assessed through behavioural testing, body composition analysis, oil red O staining and transmission electron microscopy. Mechanisms were investigated in C2C12 myotubes using lentiviral infection, Western blotting, immunofluorescence, cellular electron microscopy and seahorse assays. Finally, aged C57BL/6J mice received intramuscular AAV injections to overexpress CCN5 in skeletal muscle, evaluating its therapeutic efficacy against sarcopenia. Results: Clinical samples included 56 participants (48.2% female; mean age: 63.21 ± 8.76 years). By comparing gene expression in human skeletal muscle across three stages of sarcopenia, we identified CCN5 as a gene exhibiting decreased protein expression in possible sarcopenia stage (approximately 33% reduction, p = 0.0245), with this decline persisting into sarcopenia stage ( p = 0.0093). In young mice, CCN5 knockdown induced a sarcopenia‐like phenotype, encompassing skeletal muscle dysfunction and myosteatosis (fat mass: p < 0.01; intramyocellular triglyceride: 66.02 ± 3.798 vs. 104.5 ± 8.542 μg/mg tissue, p < 0.01). CCN5 deficiency also impaired mitochondrial content and function, particularly by reducing lipid droplet‐mitochondrial (LD‐Mt) interaction (approximately 47% reduction, p < 0.05). In C2C12 cells, CCN5 knockdown disrupted lipid metabolism (particularly reduced lipid oxidation, CPT1A: approximately 56% reduction, p < 0.001), promoted lipid accumulation and compromised mitochondrial content and function. Mechanistically, secreted CCN5 enhanced LD‐Mt interaction and stimulated mitochondrial biogenesis by activating nuclear β‐catenin translocation to enhance FOXO3A‐dependent transcription, while intracellular CCN5 mitigated myosteatosis by inhibiting PPARγ signalling. In aged mice, CCN5 overexpression improved skeletal muscle function, reduced myosteatosis (fat mass: p < 0.001; intramyocellular triglyceride: 175.0 ± 11.18 vs. 92.18 ± 10.53 μg/mg tissue, p < 0.001) and restored mitochondrial function. Conclusions: CCN5 mitigates myosteatosis and counteracts sarcopenia by promoting mitochondrial biogenesis and enhancing LD‐Mt interactions through dual pathways, positioning it as a promising therapeutic target for muscle aging and sarcopenia.